12 Month Price Forecast For CRDL
Distance to CRDL Price Forecasts
CRDL Price Momentum
๐ค Considering Cardiol (CRDL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 9:43 AM UTC
CRDL Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, CRDL has a consensus that is bullish. The median price target is $8.66, with forecasts ranging from $7.84 to $9.83. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CRDL currently trading at $1.35, the median price forecast suggests a 541.5% upside. The most optimistic forecast comes from at , projecting a 628.2% upside, while at provides the most conservative target, suggesting a 480.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRDL Analyst Consensus
CRDL Price Target Range
Latest CRDL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRDL.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 18, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
Nov 20, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
Oct 24, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
Jun 26, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $10.00 |
Jun 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
Jun 7, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
May 23, 2024 | Canaccord Genuity | Edward Nash | Buy | Maintains | $8.00 |
May 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
Apr 22, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Initiates | $9.00 |
Aug 14, 2023 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $3.00 |
May 19, 2023 | Canaccord Genuity | Edward Nash | Buy | Maintains | $6.00 |
Dec 22, 2021 | Canaccord Genuity | Buy | Initiates | $0.00 | |
Dec 22, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
Dec 17, 2021 | Cantor Fitzgerald | Charles Duncan | Overweight | Initiates | $8.00 |
Dec 3, 2021 | Canaccord Genuity | Buy | Initiates | $0.00 |
Stocks Similar to Cardiol Therapeutics Inc.
The following stocks are similar to Cardiol based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Cardiol Therapeutics Inc. (CRDL) Financial Data
Cardiol Therapeutics Inc. has a market capitalization of $110.16M with a P/E ratio of -3.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -108.4%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Cardiol Therapeutics Inc. (CRDL) Company Overview
About Cardiol Therapeutics Inc.
Develops therapies for heart diseases.
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, focusing on the R&D of anti-fibrotic and anti-inflammatory therapies for heart diseases. It generates potential revenue through the development and commercialization of its product candidates, including CardiolRx and CRD-38 injection, targeting conditions such as acute myocarditis and heart failure.
Founded in 2017 and based in Oakville, Canada, the company is currently conducting Phase II clinical trials for its lead product. It has a partnership with Meros, indicating potential for collaborative development and market expansion.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
0
CEO
Mr. David G. Elsley MBA
Country
Canada
IPO Year
2018
Website
www.cardiolrx.comCardiol Therapeutics Inc. (CRDL) Latest News & Analysis
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
4 days agoCardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST. Webcast available online.
Cardiol Therapeutics' presentation at a major healthcare conference may boost investor confidence, potentially impacting stock performance and attracting attention to its therapeutic developments.
The Zacks Medical-Drugs industry is experiencing high innovation. Stocks CORT, AMRX, DYN, NKTR, and CRDL are suggested as potential portfolio additions.
Innovation in the Zacks Medical-Drugs industry suggests potential growth, making companies like CORT, AMRX, DYN, NKTR, and CRDL attractive investment opportunities.
Cardiol Therapeutics' CEO, David Elsley, announced that their lead drug, CardiolRxโข, is entering Phase III trials for recurrent pericarditis. The company focuses on heart disease therapies.
The advancement of CardiolRxโข into a late-stage Phase III trial signals potential market approval, which could significantly impact Cardiol Therapeutics' valuation and growth prospects.
3 Penny Stocks Ready to Break Out in 2025
2 months agoPenny stocks offer low prices and high return potential but are often associated with scams like pump-and-dump. Many lack financial history and brand recognition, posing risks for investors.
Penny stocks offer high risk and potential returns but often lead to losses due to scams and lack of transparency, making them a risky investment choice.
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy
2 months agoCardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) reported positive results from its Phase II MAvERIC-Pilot study, showing sustained efficacy of CardiolRx in treating recurrent pericarditis over 26 weeks.
Positive Phase II results for CardiolRx indicate strong potential for market success and revenue growth, enhancing Cardiol Therapeutics' valuation and attractiveness to investors.
Cardiol Therapeutics (NASDAQ: CRDL) reported positive results from its Phase II MAvERIC-Pilot study on CardiolRxโข for recurrent pericarditis, showing sustained pain and inflammation reduction. Next, it advances to Phase II/III trials.
Positive clinical results for CardiolRxโข indicate strong potential for treating recurrent pericarditis, advancing the companyโs pipeline and likely boosting investor confidence in future trials.
Frequently Asked Questions About CRDL Stock
What is Cardiol Therapeutics Inc.'s (CRDL) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Cardiol Therapeutics Inc. (CRDL) has a median price target of $8.66. The highest price target is $9.83 and the lowest is $7.84.
Is CRDL stock a good investment in 2025?
According to current analyst ratings, CRDL has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CRDL stock?
Wall Street analysts predict CRDL stock could reach $8.66 in the next 12 months. This represents a 541.5% increase from the current price of $1.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cardiol Therapeutics Inc.'s business model?
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, focusing on the R&D of anti-fibrotic and anti-inflammatory therapies for heart diseases. It generates potential revenue through the development and commercialization of its product candidates, including CardiolRx and CRD-38 injection, targeting conditions such as acute myocarditis and heart failure.
What is the highest forecasted price for CRDL Cardiol Therapeutics Inc.?
The highest price target for CRDL is $9.83 from at , which represents a 628.2% increase from the current price of $1.35.
What is the lowest forecasted price for CRDL Cardiol Therapeutics Inc.?
The lowest price target for CRDL is $7.84 from at , which represents a 480.8% increase from the current price of $1.35.
What is the overall CRDL consensus from analysts for Cardiol Therapeutics Inc.?
The overall analyst consensus for CRDL is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.66.
How accurate are CRDL stock price projections?
Stock price projections, including those for Cardiol Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.